Spyre Therapeutics (SYRE) Debt to Equity (2023 - 2025)
Historic Debt to Equity for Spyre Therapeutics (SYRE) over the last 3 years, with Q3 2025 value amounting to $0.02.
- Spyre Therapeutics' Debt to Equity fell 6795.65% to $0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year decrease of 6795.65%. This contributed to the annual value of $0.05 for FY2024, which is 54121.39% up from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Debt to Equity is $0.02, which was down 6795.65% from $0.13 recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Debt to Equity registered a high of $0.13 during Q2 2025, and its lowest value of -$0.79 during Q2 2023.
- Its 3-year average for Debt to Equity is -$0.04, with a median of $0.02 in 2024.
- Data for Spyre Therapeutics' Debt to Equity shows a peak YoY increase of 176377.18% (in 2025) and a maximum YoY decrease of 6795.65% (in 2025) over the last 5 years.
- Quarter analysis of 3 years shows Spyre Therapeutics' Debt to Equity stood at $0.01 in 2023, then surged by 541.21% to $0.05 in 2024, then tumbled by 50.01% to $0.02 in 2025.
- Its last three reported values are $0.02 in Q3 2025, $0.13 for Q2 2025, and $0.09 during Q1 2025.